{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T13:40:34Z","timestamp":1793799634293,"version":"4.6.1"},"reference-count":54,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T00:00:00Z","timestamp":1705881600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010887","name":"Vitaflo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010887","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013748","name":"Hope Foundation","doi-asserted-by":"publisher","award":["NCT03517085"],"award-info":[{"award-number":["NCT03517085"]}],"id":[{"id":"10.13039\/100013748","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013748","name":"Hope Foundation","doi-asserted-by":"publisher","award":["NCT03970278"],"award-info":[{"award-number":["NCT03970278"]}],"id":[{"id":"10.13039\/100013748","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013748","name":"Hope Foundation","doi-asserted-by":"publisher","award":["NCT04311307"],"award-info":[{"award-number":["NCT04311307"]}],"id":[{"id":"10.13039\/100013748","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013748","name":"Hope Foundation","doi-asserted-by":"publisher","award":["NCT05139316"],"award-info":[{"award-number":["NCT05139316"]}],"id":[{"id":"10.13039\/100013748","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013748","name":"Hope Foundation","doi-asserted-by":"publisher","award":["NCT05196165"],"award-info":[{"award-number":["NCT05196165"]}],"id":[{"id":"10.13039\/100013748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.ymgme.2024.108144","type":"journal-article","created":{"date-parts":[[2024,1,21]],"date-time":"2024-01-21T02:29:08Z","timestamp":1705804148000},"page":"108144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Treatment recommendations for glycogen storage disease type IB- associated neutropenia and neutrophil dysfunction with empagliflozin: Consensus from an international workshop"],"prefix":"10.1016","volume":"141","author":[{"given":"Sarah C.","family":"Gr\u00fcnert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry G.J.","family":"Derks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Mundy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Neil","family":"Dalton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Donadieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hofbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sema Kalkan","family":"U\u00e7ar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamas","family":"LaFreniere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique Landelino","family":"Contreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surekha","family":"Pendyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blair","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronen","family":"Spiegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolina M.","family":"Stepien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota","family":"Wesol-Kucharska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Veiga-da-Cunha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia B.","family":"Wortmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2024.108144_bb0005","series-title":"GeneReviews\u00ae","article-title":"Glycogen Storage Disease Type I","author":"Bali","year":"1993"},{"issue":"Pt 3","key":"10.1016\/j.ymgme.2024.108144_bb0010","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1042\/bj3620513","article-title":"The glucose-6-phosphatase system","volume":"362","author":"van Schaftingen","year":"2002","journal-title":"Biochem. J."},{"key":"10.1016\/j.ymgme.2024.108144_bb0015","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1067\/mpd.2000.105232","article-title":"Neutropenia, neutrophil dysfunction, and inflammatory bowel disease in glycogen storage disease type Ib: results of the European Study on Glycogen Storage Disease type I","volume":"137","author":"Visser","year":"2000","journal-title":"J. Pediatr."},{"issue":"Suppl. 1","key":"10.1016\/j.ymgme.2024.108144_bb0020","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1007\/s00431-002-1010-0","article-title":"Granulocyte colony-stimulating factor in glycogen storage disease type 1b. Results of the European Study on Glycogen Storage Disease Type 1","volume":"161","author":"Visser","year":"2002","journal-title":"Eur. J. Pediatr."},{"issue":"35","key":"10.1016\/j.ymgme.2024.108144_bb0025","first-page":"529","article-title":"Recombinant human G-CSF (Lenograstim) for infectious complications in glycogen storage disease type Ib. report of 7 cases","volume":"1994","author":"Donadieu","year":"1978","journal-title":"Nouv. Rev. Fr. Hematol."},{"key":"10.1016\/j.ymgme.2024.108144_bb0030","first-page":"252","article-title":"Patient-reported outcomes on empagliflozin treatment in glycogen storage disease type Ib: an international questionnaire study","volume":"64","author":"Gr\u00fcnert","year":"2023","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2024.108144_bb0035","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/MOH.0000000000000474","article-title":"Neutropenia in glycogen storage disease Ib: outcomes for patients treated with granulocyte colony-stimulating factor","volume":"26","author":"Dale","year":"2019","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.ymgme.2024.108144_bb0040","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/1752-1947-2-319","article-title":"A patient with glycogen storage disease type Ib presenting with acute myeloid leukemia (AML) bearing monosomy 7 and translocation t(3;8)(q26;q24) after 14 years of treatment with granulocyte colony-stimulating factor (G-CSF): a case report","volume":"2","author":"Schroeder","year":"2008","journal-title":"J Med Case Reports"},{"key":"10.1016\/j.ymgme.2024.108144_bb0045","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/00043426-200212000-00015","article-title":"Acute myelogenous leukemia and glycogen storage disease 1b","volume":"24","author":"Pinsk","year":"2002","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.ymgme.2024.108144_bb0050","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1073\/pnas.1816143116","article-title":"Failure to eliminate a phosphorylated glucose analog leads to neutropenia in patients with G6PT and G6PC3 deficiency","volume":"116","author":"Veiga-da-Cunha","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2024.108144_bb0055","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/jimd.12187","article-title":"Inborn errors of metabolite repair","volume":"43","author":"Veiga-da-Cunha","year":"2020","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2024.108144_bb0060","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00018-023-04884-8","article-title":"SGLT5 is the renal transporter for 1,5-anhydroglucitol, a major player in two rare forms of neutropenia","volume":"80","author":"Diederich","year":"2023","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ymgme.2024.108144_bb0065","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.3390\/diagnostics13101803","article-title":"Treatment of the neutropenia associated with GSD1b and G6PC3 deficiency with SGLT2 inhibitors","volume":"13","author":"Veiga-da-Cunha","year":"2023","journal-title":"Diagnostics (Basel)."},{"key":"10.1016\/j.ymgme.2024.108144_bb0070","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.gim.2022.04.001","article-title":"Efficacy and safety of empagliflozin in glycogen storage disease type Ib: data from an international questionnaire","volume":"24","author":"Gr\u00fcnert","year":"2022","journal-title":"Genet. Med."},{"issue":"Supplement 1","key":"10.1016\/j.ymgme.2024.108144_bb0075","doi-asserted-by":"crossref","first-page":"8320","DOI":"10.1182\/blood-2022-169243","article-title":"Oral SGLT2 inhibitors in glycogen storage disease type Ib and G6PC3-deficiency. Preliminary results from an off-label study of 21 patients","volume":"140","author":"Donadieu","year":"2022","journal-title":"Blood."},{"key":"10.1016\/j.ymgme.2024.108144_bb0080","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s13023-020-01503-8","article-title":"Improved inflammatory bowel disease, wound healing and normal oxidative burst under treatment with empagliflozin in glycogen storage disease type Ib","volume":"15","author":"Gr\u00fcnert","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2024.108144_bb0085","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1182\/blood.2019004465","article-title":"Treating neutropenia and neutrophil dysfunction in glycogen storage disease type Ib with an SGLT2 inhibitor","volume":"136","author":"Wortmann","year":"2020","journal-title":"Blood."},{"key":"10.1016\/j.ymgme.2024.108144_bb0090","first-page":"303","article-title":"Two successful pregnancies and first use of empagliflozin during pregnancy in glycogen storage disease type Ib","volume":"63","author":"Gr\u00fcnert","year":"2022","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2024.108144_bb0095","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s13052-021-01100-w","article-title":"Crohn disease-like enterocolitis remission after empagliflozin treatment in a child with glycogen storage disease type Ib: a case report","volume":"47","author":"Rossi","year":"2021","journal-title":"Ital. J. Pediatr."},{"key":"10.1016\/j.ymgme.2024.108144_bb0100","first-page":"199","article-title":"Sodium-glucose cotransporter type 2 channel inhibitor: breakthrough in the treatment of neutropenia in patients with glycogen storage disease type 1b?","volume":"63","author":"Kaczor","year":"2022","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2024.108144_bb0105","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1111\/ped.14629","article-title":"Empagliflozin ameliorated neutropenia in a girl with glycogen storage disease Ib","volume":"63","author":"Mikami","year":"2021","journal-title":"Pediatr. Int."},{"key":"10.1016\/j.ymgme.2024.108144_bb0110","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s13023-022-02345-2","article-title":"Understanding the role of SGLT2 inhibitors in glycogen storage disease type Ib: the experience of one UK centre","volume":"17","author":"Halligan","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2024.108144_bb0115","first-page":"309","article-title":"Untargeted metabolomic profiling in a patient with glycogen storage disease Ib receiving empagliflozin treatment","volume":"63","author":"Tallis","year":"2022","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2024.108144_bb0120","doi-asserted-by":"crossref","first-page":"1071464","DOI":"10.3389\/fped.2022.1071464","article-title":"Favorable outcome of empagliflozin treatment in two pediatric glycogen storage disease type 1b patients","volume":"10","author":"Hexner-Erlichman","year":"2022","journal-title":"Front. Pediatr."},{"key":"10.1016\/j.ymgme.2024.108144_bb0125","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.5114\/aoms\/150029","article-title":"The overall benefits of empagliflozin treatment in adult siblings with glycogen storage disease type Ib: one year experience","volume":"18","author":"Bidiuk","year":"2022","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.ymgme.2024.108144_bb0130","article-title":"Repurposing of Empagliflozin as a possible treatment for neutropenia and inflammatory bowel disease in glycogen storage disease type Ib: a case report","volume":"14","author":"Makrilakis","year":"2022","journal-title":"Cureus."},{"key":"10.1016\/j.ymgme.2024.108144_bb0135","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/jimd.12246","article-title":"View from inside: Nina, glycogen storage disease warrior","volume":"43","year":"2020","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2024.108144_bb0140","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1542\/peds.2004-1260","article-title":"American Academy of Pediatrics steering committee on quality improvement and management. Classifying recommendations for clinical practice guidelines","volume":"114","year":"2004","journal-title":"Pediatrics."},{"key":"10.1016\/j.ymgme.2024.108144_bb0145","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/jimd.12509","article-title":"Successful use of empagliflozin to treat neutropenia in two G6PC3-deficient children: impact of a mutation in SGLT5","volume":"45","author":"Boulanger","year":"2022","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2024.108144_bb0150","series-title":"Jardiance - Summary of Product Characteristics","author":"European Medicines Agency","year":"2023"},{"key":"10.1016\/j.ymgme.2024.108144_bb0155","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.2147\/DDDT.S221093","article-title":"Remogliflozin Etabonate in the treatment of type 2 diabetes: design, development, and place in therapy","volume":"14","author":"Mohan","year":"2020","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ymgme.2024.108144_bb0160","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1093\/cvr\/cvaa323","article-title":"Off-target effects of sodium-glucose co-transporter 2 blockers: empagliflozin does not inhibit Na+\/H+ exchanger-1 or lower [Na+]i in the heart","volume":"117","author":"Chung","year":"2021","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ymgme.2024.108144_bb0165","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1111\/dme.13629","article-title":"Pharmacokinetic and pharmacodynamic profile of the sodium-glucose co-transporter-2 inhibitor empagliflozin in young people with type 2 diabetes: a randomized trial","volume":"35","author":"Laffel","year":"2018","journal-title":"Diabet. Med."},{"key":"10.1016\/j.ymgme.2024.108144_bb0170","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1056\/NEJMra035092","article-title":"Developmental pharmacology--drug disposition, action, and therapy in infants and children","volume":"349","author":"Kearns","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 10","key":"10.1016\/j.ymgme.2024.108144_bb0175","first-page":"S10","article-title":"Developmental changes in pharmacokinetics and pharmacodynamics","volume":"58","author":"van den Anker","year":"2018","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ymgme.2024.108144_bb0185","article-title":"Liver transplantation in glycogen storage disease type Ib: the role of SGLT2 inhibitors","volume":"35","author":"Murko","year":"2023","journal-title":"Mol Genet Metab Rep."},{"key":"10.1016\/j.ymgme.2024.108144_bb0190","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1182\/blood-2016-01-688887","article-title":"Neutrophil heterogeneity: implications for homeostasis and pathogenesis","volume":"127","author":"Silvestre-Roig","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.ymgme.2024.108144_bb0195","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s12020-012-9760-6","article-title":"1,5-Anhydroglucitol in diabetes mellitus","volume":"43","author":"Kim","year":"2013","journal-title":"Endocrine."},{"key":"10.1016\/j.ymgme.2024.108144_bb0200","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2337\/dc11-1462","article-title":"Serum 1,5-anhydroglucitol concentrations are a reliable index of glycemic control in type 2 diabetes with mild or moderate renal dysfunction","volume":"35","author":"Kim","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ymgme.2024.108144_bb0205","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1586\/14737159.8.1.9","article-title":"1,5-anhydroglucitol (GlycoMark) as a marker of short-term glycemic control and glycemic excursions","volume":"8","author":"Dungan","year":"2008","journal-title":"Expert Rev. Mol. Diagn."},{"key":"10.1016\/j.ymgme.2024.108144_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2023.107712","article-title":"DBS are suitable for 1,5-anhydroglucitol monitoring in GSD1b and G6PC3-deficient patients taking SGLT2 inhibitors to treat neutropenia","volume":"140","author":"Dewulf","year":"2023","journal-title":"Mol. Genet. Metab."},{"issue":"2 Pt 1","key":"10.1016\/j.ymgme.2024.108144_bb0215","first-page":"E268","article-title":"Origin and disposal of 1,5-anhydroglucitol, a major polyol in the human body","volume":"263","author":"Yamanouchi","year":"1992","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.ymgme.2024.108144_bb0220","first-page":"39","article-title":"Vitamin E improves clinical outcome of patients affected by glycogen storage disease type Ib","volume":"25","author":"Melis","year":"2016","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2024.108144_bb0225","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s12602-017-9372-9","article-title":"Effect of VSL#3 probiotic in a patient with glycogen storage disease type Ia and irritable bowel disease-like disease","volume":"11","author":"Carnero-Gregorio","year":"2019","journal-title":"Probiotics Antimicrob Proteins."},{"key":"10.1016\/j.ymgme.2024.108144_bb0230","doi-asserted-by":"crossref","DOI":"10.1097\/PG9.0000000000000356","article-title":"Clinical remission of severe Crohn\u2019s disease with Empagliflozin monotherapy in a pediatric patient with glycogen storage disease type 1b","volume":"4","author":"Collen","year":"2023","journal-title":"JPGN Reports."},{"issue":"Suppl. 1","key":"10.1016\/j.ymgme.2024.108144_bb0235","first-page":"S120","article-title":"Consensus guidelines for management of glycogen storage disease type 1b - European study on glycogen storage disease type 1","volume":"161","author":"Visser","year":"2002","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.ymgme.2024.108144_bb0240","doi-asserted-by":"crossref","DOI":"10.1038\/gim.2014.128","article-title":"Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics","volume":"16","author":"Kishnani","year":"2014","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2024.108144_bb0245","first-page":"29","article-title":"A retrospective study of eating and psychosocial problems in patients with hepatic glycogen storage diseases and idiopathic ketotic hypoglycemia: towards a standard set of patient-reported outcome measures","volume":"63","author":"Venema","year":"2022","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2024.108144_bb0250","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2147\/IJNRD.S135899","article-title":"Sodium-glucose cotransporter-2 inhibition and acidosis in patients with type 2 diabetes: a review of US FDA data and possible conclusions","volume":"10","author":"D\u2019Elia","year":"2017","journal-title":"Int J Nephrol Renovasc Dis."},{"key":"10.1016\/j.ymgme.2024.108144_bb0255","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1155\/1999\/506915","article-title":"The Crohn\u2019s disease activity index, its derivatives and the inflammatory bowel disease questionnaire: a review of instruments to assess Crohn\u2019s disease","volume":"13","author":"Yoshida","year":"1999","journal-title":"Can. J. Gastroenterol."},{"key":"10.1016\/j.ymgme.2024.108144_bb0260","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1038\/ajg.2010.143","article-title":"Appraisal of the pediatric Crohn\u2019s disease activity index on four prospectively collected datasets: recommended cutoff values and clinimetric properties","volume":"105","author":"Turner","year":"2010","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.ymgme.2024.108144_bb0265","doi-asserted-by":"crossref","first-page":"1116864","DOI":"10.3389\/fendo.2023.1116864","article-title":"Continuous glucose monitoring for children with hypoglycaemia: evidence in 2023","volume":"14","author":"Worth","year":"2023","journal-title":"Front Endocrinol (Lausanne)."},{"key":"10.1016\/j.ymgme.2024.108144_bb0270","doi-asserted-by":"crossref","first-page":"1215356","DOI":"10.3389\/fendo.2023.1215356","article-title":"Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence","volume":"14","author":"Muller","year":"2023","journal-title":"Front Endocrinol (Lausanne)."},{"key":"10.1016\/j.ymgme.2024.108144_bb0275","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/jimd.12178","article-title":"Research priorities for liver glycogen storage disease: an international priority setting partnership with the James Lind Alliance","volume":"43","author":"Peeks","year":"2020","journal-title":"J. Inherit. Metab. Dis."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719224000283?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719224000283?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T17:45:13Z","timestamp":1762364713000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719224000283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S1096719224000283"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2024.108144","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment recommendations for glycogen storage disease type IB- associated neutropenia and neutrophil dysfunction with empagliflozin: Consensus from an international workshop","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2024.108144","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108144"}}